The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
TScan Therapeutics Q2 EPS $(7.69) Down From $(6.18) YoY, Sales $2.85M
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(7.69) per share. This is a 24.43 percent decrease over losses of $(6.18) per share from the same period last year. The company reported $2.85 million in
‘Buy These 2 New Stocks Before They Double, Say Analysts tipranks.com/news/article/b… $TCRX $ERAS’ -Tweet From TipRanks
https://twitter.com/TipRanks/status/1427269639889899526
Cowen & Co. Initiates Coverage On TScan Therapeutics with Outperform Rating
Cowen & Co. analyst Boris Peaker initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Outperform rating.
Morgan Stanley Initiates Coverage On TScan Therapeutics with Overweight Rating, Announces Price Target of $22
Morgan Stanley analyst Vikram Purohit initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Overweight rating and announces Price Target of $22.
Jefferies Initiates Coverage On TScan Therapeutics with Buy Rating, Announces Price Target of $21
Jefferies analyst Chris Howerton initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Buy rating and announces Price Target of $21.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.